Results of a phase III trial investigating the addition of rituximab to chemotherapy in B-cell ALL.
Addition of clofarabine to cytarabine consolidation therapy showed significantly improved DFS in patients with higher-risk AML without SCT.
In this phase III study, addition of ATO allowed anthracycline dose to be reduced; event-free survival improved over historic controls.
Combining venetoclax with azacitidine or decitabine as initial therapy was tolerable and active in elderly patients with AML.
Results from this phase III trial suggest that addition of ATO to frontline chemotherapy may further reduce relapse rates in APL.
Early data suggest potential clinical benefit from this combination.
In this phase III trial, radotinib associated with higher molecular response and lower treatment failure vs imatinib.
Retrospective observational data indicated that ponatinib achieved significantly longer OS in T315I+ CP-CML vs alloSCT.
Midostaurin added to chemotherapy significantly improved survival vs placebo in patients with FLT3-mutated AML.
Early data suggest that blinatumomab monotherapy has antileukemic activity in Ph+ B-precursor ALL after failure on TKI therapy.
Patients with complete MRD response after blinatumomab treatment had prolonged OS, RFS, and DoR vs those with an incomplete MRD response.
Potent and durable antitumor activity seen in pediatric patients with relapsed/refractory ALL.
MRD-negative CR following 19-28z CAR T-cell infusion associated with superior OS.
Addition of targeted therapy to chemotherapy increased efficacy with low rate of severe AEs.
In a subanalysis of a phase II trial, patients with R/R B-precursor ALL after alloHSCT achieved a 45% CR/CRh rate with blinatumomab treatment.
In this Expert Analysis, Elias Jabbour, MD, and Farhad Ravandi, MD, review and discuss the clinical relevance of key studies in acute and chronic leukemias presented at the 2015 ASH annual meeting.
Elias Jabbour, MD, and Farhad Ravandi, MD, review key studies and data presented at the 2015 American Society of Hematology Annual Meeting relevant to the management of patients with acute leukemias and chronic leukemias.
DA-EPOCH-R highly active in Burkitt lymphoma with reduced toxicity vs high-intensity treatment regimens.
Fewer AEs and significantly longer PFS and ORR with ibrutinib vs temsirolimus.
Phase II data suggest that the chemotherapy-free regimen of ibrutinib plus rituximab is highly active in treatment-naive FL.
Ibrutinib is active in primary CNS lymphoma, achieving clinically meaningful CSF concentrations.
In this phase III trial that enrolled elderly treatment-naive patients with CLL, ibrutinib was associated with significant reductions in risk of progression and death vs chlorambucil.
In this phase II trial, R-bendamustine induction showed similar response rates, 2-year PFS, and 2-year OS with less hematologic and marrow toxicity vs R-hyperCVAD.
Use of interim PET allows more patients to avoid IFRT while still achieving 3-year PFS.
Phase I/II data suggest promise of combining brentuximab vedotin with ESHAP for patients with relapsed/refractory cHL who are transplantation candidates.
In this early study, pembrolizumab was highly active with durable responses in heavily pretreated patients with cHL who had failed brentuximab vedotin.
Alternate kinase inhibitor therapy following ibrutinib or idelalisib discontinuation can be efficacious.
Addition of 2 doses of bortezomib to frontline R-CHOP resulted in similar 2-year PFS rates in non-GCB DLBCL defined by the Hans IHC method.
Preliminary data show promising activity for the combination of venetoclax and rituximab, including an ORR of 86% and durable responses in the 55% of patients who achieved MRD negativity.
In this early-stage study, ACP-196 demonstrated promising activity in high-risk R/R CLL regardless of the presence of del(17p).
In this expert analysis, John M. Burke, MD, and Brad S. Kahl, MD, discuss the most clinically relevant data on the management of lymphomas presented at the 2015 American Society of Hematology annual meeting.
Combination idelalisib plus BR therapy significantly improved survival outcomes in patients with R/R CLL.
Single-agent venetoclax is active and achieved deep responses in relapsed/refractory CLL with del(17p).
In this downloadable slideset, John M. Burke, MD, and Brad S. Kahl, MD, review data from key studies in lymphoma presented at the 2015 American Society of Hematology Annual Meeting.
Promising early-phase results suggest potential benefit to telomerase inhibition in RARS/RARS-T.
PRM-151 was well tolerated with observed reductions in bone marrow fibrosis and symptom scores, as well as improved anemia, thrombocytopenia.
Benefits from pacritinib observed regardless of baseline characteristics, including platelet count.
Durable efficacy with reductions in bone marrow fibrosis, JAK2 V617F allele burden, and risk of death sustained over longer-term use of ruxolitinib.
PegIFN2a is effective treatment for ET/PV as shown by favorable long-term hematologic and molecular responses.
Reduced splenomegaly observed with the combination, and patients with JAK2 mutations achieved higher response rates vs those without.
Ruxolitinib addition to IFN-α2 showed early activity with a manageable toxicity profile in tx-experienced MPN.
Combination therapy was well tolerated and showed preliminary efficacy similar to single-agent ruxolitinib.
A combination of ruxolitinib + pomalidomide showed reduction of splenomegaly and improvement of cytopenia in some patients with pretreated and high-risk MF.
SF3B1 mutations demonstrated favorable prognostic significance in multivariable survival model of MDS and several additional mutations were associated with adverse prognosis.
Phase II data suggest that eltrombopag is effective with a toxicity profile similar to placebo.
Data from this small study suggest rigosertib plus azacitidine therapy may be effective and safe in this setting.
Randomized, placebo-controlled phase II trial evaluated this novel combination in patients with previously untreated MDS.
Improvement in anemia and reduced transfusion burden sustained for up to 1 year.
Overall response rate 59% among patients with lower-risk MDS treated with low-dose azacitidine or decitabine.
In this expert analysis, Jamile Shammo, MD, FASCP, FACP, and Rami S. Komrokji, MD, discuss the clinical relevance of key findings in myelodysplastic syndromes and myeloproliferative neoplasms presented at the 2015 American Society of Hematology Annual Meeting.
In this downloadable slideset, Rami S. Komrokji, MD, and Jamile Shammo, MD, FASCP, FACP, review data from key studies in myelodysplastic syndrome and myeloproliferative neoplasms presented at the 2015 American Society of Hematology Annual Meeting.
MRD negativity at 10-6 level (using next generation sequencing) strongly predicts PFS.
Addition of bortezomib to lenalidomide plus dexamethasone induction significantly improves survival in patients with newly diagnosed MM without plans for immediate ASCT.
First all-oral proteasome inhibitor–based combination showed promising efficacy and manageable toxicity in untreated MM.
Long-term bortezomib-based therapy improves survival, including patients with del(17p) or renal impairment.
At the 3-year follow-up, addition of elotuzumab to lenalidomide/dexamethasone reduced risk of disease progression or death by 27%.
Weekly carfilzomib/dexamethasone is active with similar or lower toxicity than historical data with standard twice-weekly dosing.
Results from IFM 2009, which addressed the role of ASCT in the era of effective triplet combination therapy, showed improved PFS and suggest that ASCT in newly diagnosed myeloma should remain a standard of care.
VTD showed superior rates of ≥ VGPR vs VCD as induction therapy. Treatment with VCD resulted in higher rates of hematologic toxicity, whereas VTD resulted in more peripheral neuropathy.
PET/CT after 3 cycles of systemic therapy and before maintenance predictive of efficacy endpoints in younger patients receiving RVD.
Early results with pembrolizumab plus lenalidomide/dexamethasone show promising efficacy and acceptable safety profile in a heavily pretreated population of R/R MM.
Early results show promising efficacy and acceptable safety profile in a heavily pretreated population.
In this early analysis, combining daratumumab with pomalidomide/dexamethasone showed promising responses in heavily pretreated patients and was tolerable.
Newly FDA approved ixazomib combination therapy with lenalidomide/dexamethasone prolongs PFS and increases response rate in patients with R/R MM.
Carfilzomib plus filanesib vs single-agent carfilzomib associated with longer median PFS for patients with pretreated R/R MM.
In this activity, Shaji Kumar, MD, and Sagar Lonial, MD, discuss the clinical impact of emerging data presented at the 2015 ASH annual meeting on the treatment of patients with newly diagnosed or relapsed/refractory multiple myeloma.
Early study suggests activity of CAR-BCMA T cells in myeloma.
In this downloadable slideset, Shaji Kumar, MD, and Sagar Lonial, MD, review data from key studies in multiple myeloma presented at the 2015 American Society of Hematology Annual Meeting.
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.